Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02199665 · ClinicalTrials.gov registry record · Phase 1
Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
NCT02199665 is a Phase 1 study that has completed, run by University of Chicago. The registered enrollment target is 52 participants.
The verdict
NCT02199665, a Phase 1 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of selinexor and carfilzomib when given together with dexamethasone in treating patients with multiple myeloma that has returned or does not respond to treatment. Drugs used in chemotherapy, such as selinexor and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving selinexor, carfilzomib, and dexamethasone may be a better treatment for multiple myeloma.
Interventions
- DRUG dexamethasone
- DRUG carfilzomib
- DRUG selinexor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2014-06-12 |
| Est. Completion | 2025-10-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02199665
The ClinicalTrials.gov registry entry for NCT02199665 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which dexamethasone is the first listed.
NCT02199665 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02199665 about?
NCT02199665 is a clinical study titled "Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma". This phase I trial studies the side effects and best dose of selinexor and carfilzomib when given together with dexamethasone in treating patients with multiple myeloma that has returned or does not respond to treatment. Drugs used in chemotherapy, such as selinexor and dexamethasone, work in differ...
What is the current status of trial NCT02199665?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2014-06-12. Estimated completion is 2025-10-25.
What interventions are being tested in trial NCT02199665?
The interventions under investigation include: dexamethasone (DRUG), carfilzomib (DRUG), selinexor (DRUG).
Who is sponsoring clinical trial NCT02199665?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.